Archives

  • 2018-07
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-07
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • Therefore a number of homoisoflavonoids may be designed in

    2023-12-01

    Therefore, a number of homoisoflavonoids may be designed in future that may be effective against angiogenesis for treating ocular neovascularization. As this CVT 10216 current study deals with robust molecular modeling techniques on SH-11037 (cpd 15) and related homoisoflavonoids and SH-11037 has gained success in combination with anti-VEGF treatment CVT 10216 [39], structural information resulted from this current molecular modeling techniques may surely be helpful in designing better effective homoisoflavonoids in future to combat ocular neovascularization.
    Conflicts of interest
    Acknowledgements One of the authors, NA is grateful to University Grants Commission (UGC), New Delhi, India for providing Rajiv Gandhi National Fellowship (Grant No. F1-17.1/2014-15/RGNF-2014-15-SC-WES-73725/SA-III/Website). SG is thankful for the Start up grant from University Grants Commission (UGC), New Delhi, India (No. F.30-106/2015-BSR). We also thank to the authority of Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India and Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, India for providing facility. We sincerely appreciate the comments of learned reviewers and Editor which helped to modify the manuscript in its current form.
    Introduction Each year, there are approximately 64 000 new cases of renal cell carcinoma (RCC) in the USA, and 14 000 deaths [1]. Clear-cell histology is the most common histology, accounting for 75–80% of all RCC cases. Surgical resection with nephrectomy has been the standard of care for nonmetastatic RCC, with close surveillance afterwards. However, despite surgical resection, approximately one-third of patients experience relapse [2]. Given their efficacy and survival benefit in the metastatic RCC setting, antiangiogenics, also known as VEGF tyrosine kinase inhibitors (TKIs), have been studied in the adjuvant setting to evaluate their efficacy in potentially decreasing the rate of relapse and enhancing cure. Several trials utilizing different VEGF TKIs have been completed and reported conflicting results [3], [4], [5], [6], [7].
    Evidence acquisition The reporting of this systematic review follows the Preferred Reporting Items for Systematic Review and Meta-Analyses statement [8].
    Evidence synthesis
    Conclusions : Thai H. Ho had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Sonbol, Ho, Firwana. Acquisition of data: Sonbol, Hilal, Almader-Douglas. Analysis and interpretation of data: Sonbol, Firwana, Ho, Wang. Drafting of the manuscript: Sonbol, Hilal, Firwana, Wang, Joseph, Ho. Critical revision of the manuscript for important intellectual content: Sonbol, Hilal, Joseph, Ho. Statistical analysis: Wang, Firwana. Obtaining funding: None. Administrative, technical, or material support: Sonbol, Ho. Supervision: Ho. Other: None. Thai H. Ho certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Thai H. Ho has served on advisory boards for Pfizer, Genentech, and Exelixis. Richard W. Joseph has acted as a consultant for BMS, Exelixis, Novartis, Merck, and Incyte. The remaining authors have nothing to disclose. None. We acknowledge the support provided by the Gloria A. and Thomas J. Dutson Jr. Kidney Research Endowment. This work was supported by a Gerstner Family Career Development Award (T.H.H.) and Department of Defense grant W81XWH-17-1-0546 (T.H.H.). The opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense.